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Whereas some cytokines, such as interleukin-l or 
tumor necrosis factor-a, have pleiotropic biologic 
properties, others seem to be more restricted in their 
biologic behavior. Interleukin-l and tumor necrosis 
factor-a are known to induce the tissue accumulation 
of a mixed leukocyte infiltrate when injected into 
skin. Although both cytokines alone are not chemo­
tactic, they can induce the production of secondary 
leukotactic cytokines in cells and therefore represent 
primary cytokines. A recently detected f'amily of 
secondary and chemotactic cytokines, termed che­
mokines, now comprises 17 human members with 
leukocyte-selective chemotactic properties. Mem­
bers of the so-called " C-X-C " chemokine subf'amily, 
such as interleukin-8, Gro-a, and possibly the 'Y-in­
terf'eron-inducible protein IP-I0, seem to be impor­
tant f'or neutrophil- and/or T -lymphocyte-selective 
accumulation in inflamed skin because of' their more 
neutrophil- or T -lymphocyte-, but not monocyte- or 
M ore than 20 years ago, it was recognized that immune-competent cells are able to secrete soluble, specific proteinaceous mediators, now termed cytokines, which facilitate communica­tion between diJferent types of cells. Some of 
these cytokines have pleiotropic biologic properties, whereas others 
are more selective and restricted in their biologic behavior. Some of 
the cytokines seem to function as inducers of others. These diJferent 
properties led to a classification of cytokines as either "primary" or 
"secondary" [1], a strategy that is more instructive than absolute. 
Primary cytokines often show in vivo activities not found in vitro 
because of indirect elfects upon target cells, which either directly 
respond to this type of cytokine or induce the release of other 
cytokines with dilferent biologic properties. 
Both interleukins (IL) and tumor necrosis factors (TNF) were 
originally considered to be primary cytokines. When these cyto­
kines are injected into normal skin, several events occur: in addition 
to a wheal and Hare reaction, a mixed leukocyte infiltration into the 
dermal as well as the epidermal site can be demonstrated [2]. 
Because purified or recombinant primary cytokines are not chemo­
tactic in vitro, they presumably induce molecules important in 
trapping leukocytes in the vessels, for diapedesis and for tissue 
infiltration. Apart from the regulation of adhesion molecules in 
postcapillary venule endothelial cells. which may be important for 
Reprint requests to: Dr. Jens-M. Schroder, Department of Dermatology, 
University ofKiel, Schittenhelmstrasse 7, D-24105 Kiel, Germany. 
Abbreviations: IP-l0, interferon-,),-inducible protein-l0; MCP. mono­
cyte chemotactic and activating protein; MGSA. melanoma growth-stimu­
latory activity factor; MIP. macrophage inflammatory protein. 
eosinophil-chemotactic properties. On the other 
hand, members of' the "C-C" chemokine subf'amily, 
such as monocyte chemotactic protein-l, RANTES, 
macrophage inflammatory protein-la, and MARCI 
monocyte chemotactic protein-3, attract monocytes, 
T -lymphocyte forms and subsets, eosinophils, and 
basophils. but not neutrophils. The cell-specific che­
motactic properties as well as the release pattern, 
which seems to be at least in part tissue cell- and 
stimulus-specific, point to a possible role in chronic 
skin diseases, explaining parts of the disease-charac­
teristic tissue infiltrates. The recent detection of 
novel chemokines with T-Iymphocyte-type and sub­
population-specific chemotactic properties may f'a­
cilitate understanding of disease-characteristic pat­
terns of' T -lymphocyte accumulation, including 
homing phenomena. Kq words: chemotactic cytokinel 
chemokinelIL-8. J Invest Dermatol 105:20S-24S, 1995 
adhesion ofleukocytes to the luminal side. other primary cytokine­
dependent mechanisms are important for diapedesis and leukocyte 
trafficking. The direction of the leukocyte migration into tissue is 
critically dependent upon the generation and/or release of chemo­
tactic factors as secondary cytokines . 
CHEMOTACTIC CYTOKINES AS SECONDARY 
CYTOKINES 
There is increasing evidence that nearly all cells of the organism. 
including cells of the skin, are capable of producing secondary 
cytokines, specifically structurally related leukocyte chemotactic 
cytokines. when stimulated with primary cytokines. 
Members of this protein family, termed "chemokines" (for 
review see [3,4]). are known for their target-ceIl-selective chemo­
tactic and activating properties. Table I summarizes these leuko­
cyte-selective properties and the conditions of their generation. To 
date 17 members of the chemokine family have been identified in 
the human organism (Fig 1). 
Members of the "C-X-C" (which stands for the structural 
property of the motif cysteine-amino acid-cysteine in the amino 
terminus of the cytokine) chemokine subfamily (Fig 1). which 
includes IL-8; Gro-a. -f3. and -'}'; epithelial neutrophil-activating 
protein-78; interferon-'}' (IFN-'}')-inducible protein 10 (IF-10); 
macrophage IFN-'}'-inducible gene; granulocyte chemotactic pro­
tein-2; and the platelet proteins platelet factor-4 and neutrophil­
activating peptide-2; are at least in part chemotactic for neutrophils 
and/or T lymphocytes in vitro, but are not chemotactic or are 
minimally chemotactic for monocytes. eosinophils. or basophils 
[3,4]. In contrast, the "C-C" chemokines show two adjacent 
cysteines near the amino terminus as a conserved structural char-
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Table I. Chemokines With Possible Importance in Skin 
Chemokines' Chemotactic forb Cellular Source in Skin' Stimuli 
C-X-C type 
IL-8 PMN, T-Ly Ker, Fib, En, Me IL-l, TNF-Il' 
Gro-Il' PMN, T-Ly Ker, Fib, En, Me IL-l, TNF-Il' 
Gro-{3 PMN, ? Ker, Fib, En, Me IL-1, TNF-Il' 
Gro-y PMN,? Ker, Fib, En, Me IL-1, TNF-Il' 
ENA-78 PMN, ? Ker?, Fib? IL-1, TNF-Il' 
IP-10 T-Ly (Mo) Ker, En IFN-y 
MIG IFN-y 
GCP-2 PMN, ? IL-1, TNF-Il' 
C-C type 
MCP-1/MCAF Mo, T-Ly, Bas Ker, Fib, En, Me IFN-y, IL-1, TNF-Il' 
MCP-2 Mo,Eo ? IL-1, TNF-Il' 
MCP-3/MARC Mo, Eo, Bas Mastc. ? Allergen + IgE 
RANTES Mo, memory T-Ly, Eo, Bas Fib, Ker? TNF-Il' 
1-309 Mo ? 
MIP-11l' CD8+ T-Ly Langerhans c. 
MIP-l{3 CD4+ T-Ly ? 
CIO T-Ly Mo? IL-4 
C type 
Lymphotactin T-Ly T-Ly? 
• ENA-78, epithelial neutrophil-activating protein-78; MIG, macrophage IFN--y-inducible gene; GCP-2, granulocyte chemotactic protein-2. 
b PMN, polymorphonuclear leukocytes; T-Ly, T lymphocytes; Mo, monocytes; Bas, basophils; Eo, eosinophils. 
'Ker, keratinocytes; Fib, fibroblasts; En, endothelial cells; Me, melanocytes; Mastc., mast cells; Langerhans c., Langerhans cells. 
actenstIc (Fig 1). They are not neutrophil attractants but are 
chemotactic for monocytes, T lymphocytes and their subsets, 
basophils, eosinophils, and B-Iymphocytes and possess overlapping 
biologic properties [3,4]. 
chemokines are mediated by glycosarninoglycans. It is well known 
that these cytokines bind to glycosarninoglycans, especially heparin 
[9], and it has been suggested that glycosaminoglycans on endo­
thelial cell surfaces bind and present chemokines to selectin-bound 
leukocytes [10]. This concept has been supported by recent studies 
suggesting that chemokines may be bound to cell surface heparan 
sulfate in vivo [8,11]. 
Among the C-X-C chemokines, IL-8 appears to play an impor­
tant role for neutrophil and T -lymphocyte recruitment in vivo: 
endothelial cells, fibroblasts, and keratinocytes can produce biolog­
ically active IL-8 when stimulated with primary cytokines such as 
lL-la, lL-l{3, or TNF-a [4]. IL-8 seems to playa role in leukocyte 
adherence to endothelial cells: depending upon the form of pre­
treatInent of endothelial cells with primary cytokines, adherence of 
leukocytes (i.e., neutrophils) is either stimulated or inhibited [5,6]. 
This suggests that 1L-8 plays a role in regulation of leukocyte 
adherence and diapedesis. IL-8 is expressed on the surface of 
endothelial cells as a gradient and induces hap to tactic stimulation, 
which results in diapedesis in vitro [7]. It is interesting that IL-8 
preferentially binds to the endothelium of postcapillary venules, the 
site at which leukocyte recruitment predominantly occurs [8]. 
Tissue-specific associations of IL-8 and other heparin-binding 
REGULATION OF IL-8 PRODUCTION IN SKIN 
In vitro experiments using cultured keratinocytes, dermal fibro­
blasts, umbilical cord vein endothelial cells, and melanocytes have 
shown that primary cytokines are able to induce production ofIL-8 
in a time- and concentration-dependent manner (reviewed in 
[3,4]). Capacities of these cells to secrete 1L-8, however, depend on 
the cell type and the stimulus used. Upon primary cytokine 
stimulation, endothelial cells secrete large amounts ofIL-8 as its less 
active 77-residue-containing form [4]. In contrast, upon TNF-a 
stimulation, cultivated keratinocytes secrete less of the highly 
potent 72- and 69-residue IL-8 forms [4]. It is interesting that 
Pigure 1. Amino acid sequence alignment 
of human chemokines. Sequences (single-letter 
code of amino acids) are shown for IL-8, neutro­
phil-activating peptide-2 (NAP-2), MGSA/Gro-ll', 
Gro-(3, Gro-y, epithelial neutrophil-activating 
protein 78 (ENA 78), granulocyte chemotactic 
protein-2 (GCP-2), IP-10, macrophage IFN-'}'­
inducible gene (MIG), platelet factor-4 (PF-4), 
MIP-101, MIP-1{3, MCP-I/MCAF, MCP-2, 
MCP-3, cytokine 1-309 (1-309), and the cytokine 
RANTES. Note the presence of 10 members of 
the C-X-C subfamily (top half) and seven members 
of the C-C subfamily (bottom half). Cysteines con­
served in both subfamilies are shown in bold type, 
whereas outlets are indicated by (-) . Sequences of 
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cultivated keratinocytes show enhanced II.-8 gene expression and 
cytokine release when IFN-y is added together with TNF-a [12]. 
The amount of material released is low in comparison with that 
released by endothelial cells or monocytes [4]. In the lesional skin 
of patients with psoriasis, large amounts of biologically active IL-8 
are present, and keratinocytes may be the producer cells [13]. By 
which mechanism is II.-8 production regulated? 
A monoclonal antibody raised against purified natural IL-8 [14] 
stains normal epidermis but not the basal cell layer. This staining 
and its focal appearance or complete absence in psoriatic lesions, 
eczema, and atopic dermatitis [15,16] suggest the presence of 
preformed II.-8 immunoreactive material in normal skin and its 
release in diseased skin. Attempts to isolate biologically active IL-8 
from normal skin failed, * indicating that the immunoreactive 
material may represent biologically inactive or a less active form of 
IL-8. Indeed, attempts to purify this II.-8-like immunoreactive 
material by affinity chromatography combined with high perfor­
mance liquid chromatography and a specific II.-8 enzyme-linked 
immunosorbent assay led to the detection of material that showed 
(by Western blot analysis with II.-8 -specific monoclonal antibod­
ies) single bands with Mr higher than that of known biologically 
active variants of II.-8 (M. Sticherling, unpublished results) . In 
addition, fractions of this IL-8-1ike immunoreactive material did 
not reveal any biologic activity. 
Only IL-la could be shown to be stored in normal skin in a 
biologically active form [17]. We speculate that this is the major or 
only cellular origin oflL-1a in diseased epidermis. This hypothesis 
is supported by the idea that keratinocytes can produce biologically 
active II.-la but are unable to convert the biologically inactive 
pro-II.-1{:l into a biologically active species [17]. The presence of 
II.-1a in the absence of II.-l{:l bioactivity in epidermis points to a 
keratinocyte rather than a bone-marrow-derived cellular source 
[18]. In the case of IL-8, it is hypothesized that apart from the 
primary cytokine induction-dependent II.-8 gene expression and 
release occurring within a few hours [12], there exists a second and 
possibly faster mechanism ofIL-8 release. Preformed material (in a 
protein-bound form) may be cleaved by as yet unknown enzymatic 
mechanisms and released . 
To date, intracutaneous injection of recombinant TNF-a or 
IFN-y has not induced the depletion oflL-8-like immunoreactivity 
in normal skin. It is noteworthy that intracutaneous injection of 
II.-2 resulted in a loss of this material, t indicating that the T-cell 
infiltrate is of possible importance and may be responsible for 
release of the II.-8-like immunoreactivity. A detailed Northern 
blot analysis revealed that stimulation of HaC aT keratinocytes with 
a combination ofIFN-y and TNF-a led to formation of additional 
and higher-molecular-weight mRNA. This supports the idea of a 
two-stage II.-8 release mechanism. We do not yet know if the 
high-molecular-weight II.-8-immunoreactive material present in 
normal epidermis originates from this larger II.-8 mRNA species 
and whether it constitutes a storage form ofIL-8.:\: 
OTHER C-X-C CHEMOKINES IN THE SKIN 
To date, there is evidence for the presence of two additional C-X-C 
chemokines in the skin: lP-l0 [19] and the melanoma growth­
stimulatory activity factor (MGSA), which is identical to the 
oncogene Gro-a [20]. The expression ofIP-10 in keratinocytes and 
other cells is induced by IFN-y [21]; IP-10 has been detected during 
the development of cutaneous delayed cellular immune responses 
* Sticherling M, Schroder ]-M, Christophers E: Lack of biologically 
active interleukin 8 in normal skin (abstr). ] Invest Dermatol 95:491, 1990. 
t Bomscheuer E, Sticherling M, Schroder J-M, Christophers E: Cutane­
ous inflammatory reaction after intradermal injection of dUferent cytokines 
(abstr). Arch Dermatol Res 286:198, 1994. 
:j: Bartels], Sticherling M, Kulke R, Christophers E, Schroder J-M: The 
regulation of IL-8 mRNA expression in human keratinocytes after stimu­
lation with a combination of interferon-'Y and tumor necrosis factor-a 
involves interleukin-8 mRNA length polymorphism (abstr). Bur] Cell Bioi 
63 (suppl):40:1, 1994. 
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and in lepromatous leprosy lesions [19]. IP-l0 can be extracted 
from keratinocyte lysates and in cell supernatants if the cells are 
exposed to IFN-y [22]. As expected, when recombinant IFN-y was 
injected into the skin, 1P-10 immunoreactivity occurred in the 
epidermis [22]. The classic purified protein derivative of tuberculin 
reaction gave a similar immunostaining pattern [19]. 
Although the biologic fimction of IP-l0 was unknown until 
recendy, there is now evidence that IP-10 elicits a powerful 
host-mediated antitumor effect in vivo. The lP-l0 antitumor re­
sponse is T -lymphocyte dependent and appears to be mediated by 
. the recruitment of an inflammatory infiltrate composed mainly of 
lymphocytes and monocytes [23]. Some of the T-cell- directed 
effects ofIFN-y and lipopolysaccharide may be mediated in part by 
this chemokine or may be mediated by another C-X-C chemokine, 
macrophage IFN-y-inducible gene [24], which is also expressed in 
monocytes after stimulation with IFN-y. Recombinant 1P-10 has 
been shown to be a potent chemoattractant for stimulated (but not 
for unstimulated) T lymphocytes in vitro, with a half-maximal 
response at concentrations less than 10 ng/rnl [25] . Some activity 
also could be found for monocytes at higher doses [25], whereas 
neutrophils did not respond. IP-10 has been reported to induce 
T-cell adhesion to endothelial cells, suggesting that in addition to 
II.-l and TNF-a, IFN-y also represents a primary cytokine able to 
activate secondary cytokines in the skin. 
MGSAIGro-a has been detected as a biologically active cytokine 
in amounts comparable to those found for II.-8 in lesional psoriatic 
scale material [13] . Its biologic properties resemble those of II.-8, 
inducing neutrophil activation as well as T -lymphocyte chemotaxis 
in vitro [3,4]. It appears to play a role in cell growth regulation in 
leukocytes and as an autocrine growth factor in some melanoma 
cells [26]. Apart from tumor cells, which often express Gro-a 
mRNA without stimulation, skin cells such as fibroblasts, kerati­
nocytes, and endothelial cells are capable of expressing Gro-a 
mRNA and release biologically active material when stimulated 
with primary cytokines such as II.-l or TNF-a [3,4,27]. In all 
cultivated cell types, the relative amount of Gro-a released was 
found to be 5% to 20% of the amount of II.-8 secreted [28,29], 
whereas in diseased skin nearly equal amounts of II.-8 and MGSAI 
Gro-a can be detected [13,30]. The different ratios of these 
cytokines in disease could be due either to another potent and as yet 
unknown cellular source of Gro-a in skin, the presence of a 
selective activation mechanism for high production of Gro-a, or 
the presence of preformed Gro-a that is released under disease 
conditions. Although there is no direct evidence for the latter 
explanation, it has been shown that normal epidermis reveals 
MGSA-like immunoreactivity mainly in the stratum spino sum [26], 
which could represent preformed MGSA released under inflamma­
tory conditions, similar to the II.-8-like immunoreactivity. When 
the mRNA of different Gro forms was investigated semiquantita­
tively in psoriasis lesions, Gro-a (MGSA) was the most abundant 
form [31] . Sixfold and 25 times lower amounts ofGro-{:l and Gro-y 
message were detected, respectively [31]. Cyclosporin A did not 
affect Gro mRNA expression in keratinocyte cultures in vitro; 
however, the strong Gro-a mRNA expression in biopsy material 
obtained from psoriatic lesions was drastically reduced after treat­
ment with cyclosporin A [32]. Similarly, cyclosporin A inhibits 
other epidermal cytokines such as II.-8 gene expression [32). These 
findings led us to hypothesize that epidermal keratinocytes respond 
to signals produced by activated T lymphocytes by coordinate 
expression of multiple cytokines. 
C-C CHEMOKINES IN THE CYTOKINE NETWORK OF 
SKIN 
Whereas C-X-C chemokines such as II.-8 or Gro have been studied 
extensively, little is known about the role of C-C chemokines in 
skin. Keratinocytes, dermal fibroblasts, and endothelial cells are 
capable of producing the monocyte-chemotactic and activating 
factor MCP-l/MCAF [3]. The accumulation of monocytes in the 
epidermis and along the dermoepidermal junction in several differ­
ent inflammatory skin diseases led to the hypothesis that keratino· 
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cytes are able to produce a monocyte-specific chemotaxin. Indeed, 
cultured epidermal cells can secrete substantial amounts of the C-C 
chemokine MCP-l, which interestingly was not enhanced by 
cytokines such as IL-l/3 or TNF-a. In contrast, however, IFN-'}' 
induced a drastic up-regulation of MCP-l mRNA [33]. 
Conditions ofMCP-l production in keratinocytes are the reverse 
of those seen for IL-8 or Gro production, where both other primary 
cytokines IL-l and TNF-a induced chemokine release, whereas 
IFN-'}' had no elfect. It is interesting to speculate that MCP-l 
produced by basal keratinocytes may in part explain the accumu­
lation of dermal dendrocytes predominandy situated in the papillary 
dermis in proximity to vascular endothelium. Using in situ hybrid­
ization techniques, Gillitzer et al [34] demonstrated that MCP-l 
message is located in the basal epidermal cell layer at the tips of the 
rete ridges in psoriasis. MCP-1 was previously thought to be a 
chemotactic factor specific for monocytes. In a recent attempt to 
purify the major T -lymphocyte attractant produced by mitogen­
stimulated peripheral blood mononuclear cell preparations, two 
biochemically dilferent forms of MCP-l (but no other cytokines) 
were identified by amino acid sequencing [35]. This points to a 
possibly central role for MCP-1 in T -lymphocyte chemotaxis as 
well. 
Another C-C chemokine with potential importance in cutaneous 
inflammation is the cytokine RANTES ("regulated �d normal 
I-cell �xpressed and .§ecreted"). RANTES, originally detected as a 
eDNA expressed in normal T lymphocytes, has been reported to be 
a memory T -lymphocyte-selective chemotaxin. In addition, it is a 
chemoattractant for monocytes and eosinophils, but not for neu­
trophils [36]. Its biologic properties make this chemokine an 
attractive candidate in reactions in which memory T lymphocytes 
and eosinophils are found in inflamed tissue. Recent investigations 
have shown that skin cells can produce RANTES upon appropriate 
stimulation. Dermal fibroblasts express the gene and secrete RAN­
TES when stimulated with TNF-a. Although it has been reported 
that IL-l does not induce RANTES gene expression in these cells, 
we found strong induction.§ This could reflect a dilferent and as yet 
unknown regulatory principle. Whether normal keratinocytes can 
produce RANTES is still speculation at this juncture. We observed 
RANTES mRNA expression and protein release in keratinocyte 
cell lines when these cells were stimulated with cytokines. � 
RANTES seems to play an important role in delayed type 
hypersensitivity reactions, where two cell populations are specifi­
cally recruited at the site of the lesion: T lymphocytes of the helper, 
memory subset, and cells of the monocytic/macrophage lineage. In 
human lymph nodes presenting typical delayed type hypersensitiv­
ity lesions related to either sarcoidosis or tuberculosis, RANTES 
gene expression studies by in situ hybridization techniques revealed 
that macrophages and endothelial cells contributed to RANTES 
gene expression and protein production [37]. So far, there is no 
published information on the role of this cytokine in atopic 
dermatitis or late-phase allergic reactions. 
Macrophage inflammatory proteins (MIP-1a, /3) represent an­
other set of C-C chemokines of possible importance in the skin. 
MIP-1a and MIP-l/3 were originally detected in activated T 
lymphocytes, and now are thought �o represent a group of slightly 
variant proteins having between 94% and 98% identity, and being 
multiple nonallelic forms of both chemokines. One important 
biologic function of MIP-la appears to be the inhibition of 
hematopoietic stem cell proliferation, which is reversed by MIP-l/3 
[38]. It is interesting that murine MIP-la was found to inhibit 
keratinocyte colony formation. Expression of the MIP-1a and 
MIP-1/3 genes seemed to be restricted to hematopoietic cells. 
Mouse-skin-derived Langerhans cells showed strong expression of 
§ Kuepper 11.1, Bartels J, Kulke R. Christophers E, Schroder J-M: Tumor 
necrosis factor-IX and interleukin-1 induce RANTES mRNA expression in 
human dermal fibroblasts (abstr).} 1IIVest Derl1lato/l03:419, 1994. 
� Kuepper M, Bartels J, Kulke R, Christophers E, Schroder ]-M: 
Expression of RANTES mRNA in a human keratinocyte cell line (abstr). 
Arch DeTI1Iato/ Res (in press). 
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MIP-la mRNA, which decreased during culture, whereas other 
epidermal cells did not show any up-regulation. There is no 
information about conditions ofMIP-la or MIP-l/3 production by 
either dermal fibroblasts or keratinocytes, and it seems possible that 
these cells are unable to produce MIPs. MIP-1a has been reported 
to be a preferential and potent chemotactic factor for activated 
CDS+ T lymphocytes, whereas MIP-1/3 is seen to be an attractant 
for T lymphocytes of the CD4+ type [39]. These findings make it 
likely that MIPs are important in skin infiltration by dilferent 
lymphocyte subsets . 
OTHER CHEMOKINES 
The role of recently detected chemokines in skin is poorly under­
stood. The monocyte- and eosinophil-chemotactic activating pro­
tein MCP-3 as well as CI0 are of particular interest in the skin 
cytokine network. MCP-3 represents the human equivalent of the 
mouse chemokine MARC, which was expressed in a mouse mast 
cell line only by stimulation with allergen plus 19B, but not with 
cytokines such as IL-l or TNF-a [40]. There is no evidence that 
human epidermal cells, dermal cells, or mast cells express MCP-3 
mRNA upon stimulation. Because RANTES and MCP-3 are the 
only potent and as yet characterized eosinophil-attracting chemo­
kines, its production in skin could be of importance in allergic skin 
diseases. Recently, however, we discovered a novel and apparently 
eosinophil-selective C-C chemokine in supernatants of skin cells. 
This chemokine represents an attractive candidate for eosinophil 
infiltration into skin (N. Noso, J.-M. Schroder, unpublished re­
sults). 
Another recently detected (mouse) C-C chemokine, CI0, is to 
date functionally uncharacterized [41]. Whereas the C-C chemo­
kines MCP-1, MIP-la, and RANTES were all induced by bacterial 
lipopolysaccharides, this was not found to be the case for C10. 
Conversely, IL-3, granulocyte-macrophage colony-stimulating fuc­
tor, and IL-4 induced the C10 message, which had no elfect or a 
more restricted elfect on the expression of other chemokines. The 
possibility of a human equivalent remains unexplored. 
A novel (mouse) chemokine designated "lymphotactin" recently 
was discovered in activated pro-T cells and lacks two of the four 
cysteine residues that are characteristic of the chemokines. It 
represents the first member of a novel chemokine subfamily 
(termed "c" chemokines). Lymphotactin is also expressed in 
CD8+ T cells and in CD4- CD8- T-cell-receptor 01/3+ thymo­
cytes. It has chemotactic activity for lymphocytes, but not for 
monocytes or neutrophils [42]. Its role in the skin of the mouse and 
human is unknown. 
CONCLUSION AND OUTLOOK 
In the 1980s, the major focus of research on the cytokine network 
in the skin was on primary cytokines produced as key mediators. A 
second decade of research now focuses on newly discovered 
cytokines and cytokine families, which have more restricted bio.., 
logic properties. 
One newly discovered cytokine fumily, the chemokines, might 
be of interest for explaining the appearance of dilferent leukocyte 
types and subsets in diseased skin. The tissue- and condition­
selective local generation of these mediators, which depends upon 
the presence of important stimuli (mainly primary cytokines) for its 
formation, contributes to our understanding of the local disease­
characteristic patterns of dermal, epidermal, and focal accumulation 
of dilferent leukocyte forms and subsets . In addition to chemokines, 
which can explain only part of the phenomena seen in skin inflamma­
tion, recently characterized cytokines, e.g., interleukins (IL-9 
through IL-1S) or the CD4-binding lymphocyte chemotactic factor 
[43], might represent factors important for other biologic phenom­
ena and the (down) regulation of phenomena induced by cytokines 
in the skin. The increasing body of evidence supporting the 
existence of recently detected novel lymphocyte-chemotactic and 
activating chemokines, and other cytokines with certain subset­
specific properties, suggests that we may soon have a better 
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understanding of the regulatory mechanism of tissue-specific lym­
phocyte homing. 
Some of this work was supported by a grant from the Deutsche Forschungsgemein­
schaft, Ch 3817-1. 
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